Clinical Trials Logo

Prostatic Hyperplasia clinical trials

View clinical trials related to Prostatic Hyperplasia.

Filter by:

NCT ID: NCT00347061 Completed - Clinical trials for Benign Prostatic Hyperplasia

Long Term Safety of SL77.0499-10 (Alfuzosin) in Patients With BPH

Start date: May 2006
Phase: Phase 3
Study type: Interventional

Primary: To assess the safety of SL77.0499-10 10mg administered once daily for one year in patients with lower urinary tract symptoms related to BPH. Secondary: - To provide the information on the efficacy of SL77.0499-10 10mg administered once daily for one year in patients with lower urinary tract symptoms related to BPH. - To document the plasma concentration of SL77.0499-10 after repeated administration of SL77.0499-10 10mg administered once daily in patients with lower urinary tract symptoms related to BPH.

NCT ID: NCT00316732 Completed - Clinical trials for Prostatic Hyperplasia

Observational AVODART (Dutasteride) Study In Benign Prostatic Hyperplasia Subjects - OASIS

Start date: October 25, 2004
Phase: N/A
Study type: Observational

This study was designed to assess the effectiveness of dutasteride in the actual clinical practice of prostate assessment clinics in the UK in accordance with best practice over a 12-month period.

NCT ID: NCT00303654 Completed - Bladder Cancer Clinical Trials

Loop Resectoscope in Treating Patients With Bladder Cancer or Benign Prostatic Hyperplasia Who Are Undergoing Transurethral Resection

Start date: August 2005
Phase: N/A
Study type: Interventional

RATIONALE: Transurethral resection is a less invasive type of surgery for bladder cancer or benign prostatic hyperplasia. Transurethral resection using a loop resectoscope may have fewer side effects and improve recovery. PURPOSE: This clinical trial is studying how well the loop resectoscope works in treating patients with bladder cancer or benign prostatic hyperplasia who are undergoing transurethral resection.

NCT ID: NCT00290030 Completed - Clinical trials for Prostatic Hyperplasia

ALFAURUS : A DB Randomized Parallel Group Study of Alfuzosin 10mg OD vs Placebo in the Management of AUR in Patients With a 1st Episode Due to BPH

Start date: May 2001
Phase: Phase 3
Study type: Interventional

To assess the efficacy of alfuzosin 10mg OD in the management of acute urinary retention associated with BPH. To assess the safety of alfuzosin in this population and health care consumption.

NCT ID: NCT00284518 Completed - Clinical trials for Benign Prostatic Hyperplasia

Safety and Efficacy Study of Botulinum Toxin Type A to Treat Lower Urinary Symptoms Due to Benign Prostatic Hyperplasia

Start date: December 2005
Phase: Phase 2
Study type: Interventional

The purpose of this study was to determine the safety and effectiveness of different doses of botulinum toxin Type A in treating lower urinary tract symptoms due to benign prostatic hyperplasia.

NCT ID: NCT00280605 Completed - Clinical trials for Prostatic Hyperplasia

ALF-ONE : ALFuzosin ONcE Daily

Start date: August 2005
Phase: Phase 4
Study type: Interventional

The aim of the study is to collect, under daily practice conditions, clinical data on the safety profile and the efficacy of a new formulation of alfuzosin administered once daily in patients with lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH).

NCT ID: NCT00256399 Completed - Clinical trials for Erectile Dysfunction

Uroxatral in Men With Benign Prostate Hypertrophy (BPH) and Erectile Dysfunction (ED)

Start date: November 2005
Phase: N/A
Study type: Interventional

Uroxatral (alfuzosin) may not only help BPH symptoms but may also improve sexual function in males with BPH and ED.

NCT ID: NCT00224133 Completed - Clinical trials for Benign Prostatic Hyperplasia

The Evaluation of the Safety of a New Drug for Benign Prostatic Hyperplasia Used for 9 Months

Start date: September 2005
Phase: Phase 3
Study type: Interventional

A new drug for benign prostatic hyperplasia is used for 9 months to determine its long-term safety.

NCT ID: NCT00224120 Completed - Clinical trials for Benign Prostatic Hyperplasia

A New Drug for Benign Prostatic Hyperplasia (BPH) Compared With Placebo

Start date: May 2005
Phase: Phase 3
Study type: Interventional

A new drug for benign prostatic hyperplasia is compared to placebo for to determine if it is safe and effective. The study lasts approximately 20 weeks.

NCT ID: NCT00224107 Completed - Clinical trials for Benign Prostatic Hyperplasia (BPH)

A New Drug for Benign Prostatic Hyperplasia (BPH) Compared With Placebo

Start date: May 2005
Phase: Phase 3
Study type: Interventional

A new drug for benign prostatic hyperplasia is compared to placebo for to determine if it is safe and effective. The study lasts approximately 20 weeks.